{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:22:09Z","timestamp":1791105729518,"version":"4.1.0"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2010,12,31]],"date-time":"2010-12-31T00:00:00Z","timestamp":1293753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0015298","type":"journal-article","created":{"date-parts":[[2010,12,31]],"date-time":"2010-12-31T16:40:33Z","timestamp":1293813633000},"page":"e15298","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":121,"title":["Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial"],"prefix":"10.1371","volume":"5","clinical-trial-number":[{"clinical-trial-number":"umin000000780","registry":"10.18810\/umin-japan"}],"author":[{"given":"Hideyuki","family":"Sawada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Oeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadako","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinya","family":"Hisanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Amantadine Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2010,12,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jnnp.62.1.10","article-title":"Prevalence of parkinsonism and Parkinson&apos;s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson&apos;s disease.","volume":"62","author":"MC de Rijk","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1474-4422(08)70291-6","article-title":"Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson&apos;s disease.","volume":"8","author":"AL Benabid","year":"2009","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of the motor complications of Parkinson&apos;s disease on the quality of life.","volume":"20","author":"S Chapuis","year":"2005","journal-title":"Mov Disord"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.","volume":"130","author":"M Carta","year":"2007","journal-title":"Brain"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1523\/JNEUROSCI.0676-04.2004","article-title":"Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease.","volume":"24","author":"JC Corvol","year":"2004","journal-title":"J Neurosci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuropharm.2004.11.008","article-title":"Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson&apos;s disease.","volume":"48","author":"PJ Hallett","year":"2005","journal-title":"Neuropharmacology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1523\/JNEUROSCI.1176-08.2008","article-title":"Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements.","volume":"28","author":"L Liang","year":"2008","journal-title":"J Neurosci"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1523\/JNEUROSCI.16-07-02397.1996","article-title":"The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons.","volume":"16","author":"CJ Wilson","year":"1996","journal-title":"J Neurosci"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1523\/JNEUROSCI.18-01-00266.1998","article-title":"Up and down states in striatal medium spiny neurons simultaneously recorded with spontaneous activity in fast-spiking interneurons studied in cortex-striatum-substantia nigra organotypic cultures.","volume":"18","author":"D Plenz","year":"1998","journal-title":"J Neurosci"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1002\/mds.22019","article-title":"Molecular mechanisms underlying levodopa-induced dyskinesia.","volume":"23","author":"P Calabresi","year":"2008","journal-title":"Mov Disord"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0922-4106(91)90113-V","article-title":"Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.","volume":"206","author":"J Kornhuber","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.parkreldis.2005.05.008","article-title":"Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.","volume":"11","author":"FP da Silva-Junior","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","article-title":"Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson&apos;s disease.","volume":"15","author":"E Luginger","year":"2000","journal-title":"Mov Disord"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002826-200003000-00004","article-title":"The effect of amantadine on levodopa-induced dyskinesias in Parkinson&apos;s disease: a double-blind, placebo-controlled study.","volume":"23","author":"BJ Snow","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"ref15","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson&apos;s disease.","volume":"75","author":"A Thomas","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson&apos;s disease.","volume":"50","author":"L Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/mds.23034","article-title":"Long-term antidyskinetic efficacy of amantadine in Parkinson&apos;s disease.","volume":"25","author":"E Wolf","journal-title":"Mov Disord"},{"key":"ref18","first-page":"CD003467","article-title":"Amantadine for dyskinesia in Parkinson&apos;s disease.","author":"NJ Crosby","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.","volume":"66","author":"R Pahwa","year":"2006","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.","volume":"285","author":"D Moher","year":"2001","journal-title":"Jama"},{"key":"ref21","first-page":"165","article-title":"Parkinson&apos;s Disease Society Brain Bank, London: overview and research.","author":"SE Daniel","year":"1993","journal-title":"J Neural Transm"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/mds.870090403","article-title":"Utility of an objective dyskinesia rating scale for Parkinson&apos;s disease: inter- and intrarater reliability assessment.","volume":"9","author":"CG Goetz","year":"1994","journal-title":"Mov Disord"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clineuro.2006.07.003","article-title":"Treatment of drug-induced psychosis in Parkinson&apos;s disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.","volume":"109","author":"J Schindehutte","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.parkreldis.2008.08.005","article-title":"Plasma amantadine concentrations in patients with Parkinson&apos;s disease.","volume":"15","author":"N Nishikawa","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archneur.63.2.205","article-title":"Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976\u20131990.","volume":"63","author":"JA Van Gerpen","year":"2006","journal-title":"Arch Neurol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/jnnp.2005.068940","article-title":"Dyskinesias induced by subthalamotomy in Parkinson&apos;s disease are unresponsive to amantadine.","volume":"77","author":"M Merello","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0015298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T09:18:05Z","timestamp":1559899085000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0015298"}},"subtitle":[],"editor":[{"given":"Tsuneya","family":"Ikezu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,12,31]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2010,12,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0015298","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,31]]}}}